245 related articles for article (PubMed ID: 8995510)
41. Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction.
Morita-Ogawa T; Sugita H; Minami H; Yamaguchi T; Hanada K
Cancer Chemother Pharmacol; 2020 Oct; 86(4):559-566. PubMed ID: 32949266
[TBL] [Abstract][Full Text] [Related]
42. Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity.
Umeki S; Tsukiyama K; Okimoto N; Soejima R
Am J Med Sci; 1989 Oct; 298(4):221-6. PubMed ID: 2552802
[TBL] [Abstract][Full Text] [Related]
43. Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer.
Reece PA; Stafford I; Davy M; Morris R; Freeman S
Cancer Chemother Pharmacol; 1989; 24(4):256-60. PubMed ID: 2752507
[TBL] [Abstract][Full Text] [Related]
44. [Combination effects of cis-dichlorodiammineplatinum (II) and sodium thiosulfate on renal dysfunction].
Hirosawa A; Sakai S; Iizuka K; Niitani H; Hayashibara K; Tsuboi E
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2870-5. PubMed ID: 3662543
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics of cisplatin in analbuminemic rats.
Takada K; Kawamura T; Inai M; Masuda S; Oka T; Yoshikawa Y; Shibata N; Yoshikawa H; Ike O; Wada H; Hitomi S
Biopharm Drug Dispos; 1999 Dec; 20(9):421-8. PubMed ID: 10951431
[TBL] [Abstract][Full Text] [Related]
46. [Studies on serum and urinary alpha 1-microglobulin levels as parameter of the renal function--renal function observed after CDDP administration].
Ujiie T; Maruta H; Ito N
Hinyokika Kiyo; 1988 May; 34(5):790-6. PubMed ID: 2459938
[TBL] [Abstract][Full Text] [Related]
47. Effects of sodium thiosulfate in combination therapy of cis-dichlorodiammineplatinum and vindesine.
Hirosawa A; Niitani H; Hayashibara K; Tsuboi E
Cancer Chemother Pharmacol; 1989; 23(4):255-8. PubMed ID: 2538252
[TBL] [Abstract][Full Text] [Related]
48. Intratumor cisplatin nephrotoxicity in combined laser-induced thermal therapy for cancer treatment.
Palumbo MN; Cervantes O; Eugênio C; Hortense FTP; Ribeiro JC; Paolini AAP; Tedesco AC; Sercarz JA; Paiva MB
Lasers Surg Med; 2017 Oct; 49(8):756-762. PubMed ID: 28598516
[TBL] [Abstract][Full Text] [Related]
49. [Prophylactic effect of fosfomycin on CDDP nephrotoxicity].
Yogi S; Ikeuchi T; Kai Y
Hinyokika Kiyo; 1989 Apr; 35(4):615-21. PubMed ID: 2735267
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study.
Stathopoulos GP; Boulikas T; Vougiouka M; Deliconstantinos G; Rigatos S; Darli E; Viliotou V; Stathopoulos JG
Oncol Rep; 2005 Apr; 13(4):589-95. PubMed ID: 15756428
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the effect of glutathione on cisplatin antitumor activity and kidney injury at different administration times.
Xu YY; Jiang N; Liu TS; Qu HQ; Wang T
Mol Med Rep; 2012 Nov; 6(5):1075-80. PubMed ID: 22895541
[TBL] [Abstract][Full Text] [Related]
52. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury.
Saleh S; Ain-Shoka AA; El-Demerdash E; Khalef MM
Chemotherapy; 2009; 55(6):399-406. PubMed ID: 19955745
[TBL] [Abstract][Full Text] [Related]
53. The renal clearance of unchanged cisplatin during furosemide and mannitol diuresis is dependent on glomerular filtration rate in rats.
Nagai N; Ogata H
J Pharm Sci; 1996 Jul; 85(7):720-4. PubMed ID: 8818996
[TBL] [Abstract][Full Text] [Related]
54. Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats.
Saad SY; Al-Rikabi AC
Chemotherapy; 2002 Mar; 48(1):42-8. PubMed ID: 11901256
[TBL] [Abstract][Full Text] [Related]
55. Alterations in Cisplatin Pharmacokinetics and Its Acute/Sub-chronic Kidney Injury over Multiple Cycles of Cisplatin Treatment in Rats.
Okada A; Fukushima K; Fujita M; Nakanishi M; Hamori M; Nishimura A; Shibata N; Sugioka N
Biol Pharm Bull; 2017; 40(11):1948-1955. PubMed ID: 29093343
[TBL] [Abstract][Full Text] [Related]
56. [A clinical phase III trial of ulinastatin (MR-20) for nephrotoxicity of cisplatin].
Nishikawa H; Nakabayashi T; Nakai Y; Kurita Y; Fukuoka M; Onoshi T; Ogura T; Sakuma A; Niitani H; Tsubura E
Gan To Kagaku Ryoho; 1998 Jan; 25(1):97-109. PubMed ID: 9464335
[TBL] [Abstract][Full Text] [Related]
57. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of nitric oxide synthase aggravates cisplatin-induced nephrotoxicity: effect of 2-amino-4-methylpyridine.
Saad SY; Najjar TA; Daba MH; Al-Rikabi AC
Chemotherapy; 2002; 48(6):309-15. PubMed ID: 12673106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
